PLA2G4A and Parkinson disease: Inhibiting the phosphorylation of S-505 and T-268 of cPLA2 or decreasing the deregulating Cdk5 kinase activity in humans could be a potential therapeutic intervention to rescue the excess neuroinflammation in the PD brain.